PT Siloam International Hospitals (SILO) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue reached Rp10,491,955 million versus Rp9,425,533 million in 9M 2025; profit for the period was Rp975,209 million versus Rp797,122 million.

• Five hospital-property companies were acquired on September 24, 2026; the total proposed 14-company transaction was valued at Rp9,000,000 million before net-asset and remaining capex adjustments.

Financial highlights

• Revenue: Rp10,491,955 million versus Rp9,425,533 million; gross profit: Rp4,039,713 million versus Rp3,597,117 million, for 9M 2026 and 9M 2025, respectively.

• Operating income was Rp1,427,371 million versus Rp1,172,336 million; profit before tax was Rp1,290,232 million versus Rp1,069,895 million.

• Net income was Rp975,209 million versus Rp797,122 million; parent-attributable income was Rp928,731 million versus Rp761,342 million.

• Basic EPS was Rp71.51 versus Rp58.63; diluted EPS was Rp71.50 versus Rp58.62, for 9M 2026 and 9M 2025, respectively.

Outlook and guidance

• Construction in progress stood at 20%–98% completion, with projects expected to finish from 2027 to 2029; management expects no impediment to completion.

• The proposed second-stage acquisition covers six hospital-property companies, valued at Rp3,879,404 million before adjustments; syndicated facilities are designated to fund the transaction.

• On October 6, 2026, Rp700,000 million was drawn from syndicated facilities, comprising Rp524,000 million from Facility A1 and Rp176,000 million from Facility A2.